9.68
-8.68%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Precision BioSciences
From its filings with the US Securities and Exchange Commission
Precision BioSciences is based in Durham, North Carolina and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DTIL. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $34.3m and a net loss of $45.7m. At that date it held total assets of $154.4m and shareholders' equity of $92.2m.
We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus (“AAV”)). We believe that the ARCUS platform’s key capabilities and differentiating characteristics can be leveraged for effective and safe therapeutic outcomes.
DNA carries the genetic instructions for all basic functions of a living cell. These instructions are encoded in four different molecules, called bases, which are strung together in specific sequences to form genes. Each gene is responsible for a specific function in a cell, and the complete set of genes in a cell, which can consist of tens of thousands of genes and billions of individual bases, is known as a genome. The complete genome sequence has been determined for many organisms, including humans. This allows scientists to identify specific genes and determine how their unique sequences contribute to a particular cellular function.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Mar 2019
- Employees
- 225
- Website
- precisionbiosciences.com ↗
- Head office
- 302 EAST PETTIGREW STREET, DURHAM, NC, 27701
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Kevin BuehlerIndependent Chairman of the Board$214,498
- Mr. Michael AmorosoPresident, Chief Executive Officer, Director, since 2021$4.3m
- Mr. Alex KellyChief Financial Officer$1.9m
- Dr. Cassie GorsuchChief Scientific Officer
- Mr. Dario ScimecaGeneral Counsel, Secretary$1.5m
- Ms. Cindy AtwellChief Development and Business Officer
- Dr. Jeff SmithChief Research Officer$1.4m
- Ms. Melinda BrownIndependent Director$184,998
- Dr. Stanley FrankelIndependent Director$182,248
- Mr. Geno GermanoIndependent Director$195,748
- Ms. Shari PireIndependent Director$184,248
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 50
- Social
- 56
- Governance
- 18
- Women in the workforce
- 51%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Precision BioSciences employs 225 full-time employees in Durham, North Carolina.
- The ARCUS genome editing technology enables precise DNA modification at any genome location.
- The company develops four CAR T cell product candidates including PBCAR0191 and PBCAR20A.
Weaknesses
- The company has only four product candidates in its CAR T cell pipeline.
- Precision BioSciences has been listed since March 28, 2019, with limited market history.
- The firm focuses on genome editing for therapeutic, agricultural, and biologics manufacturing applications.
Opportunities
- The ARCUS platform offers potential for human disease treatment and sustainable food solutions.
- Precision BioSciences can expand its genome editing applications in the Health Care sector.
- The company's technology may address limitations in other genome editing technologies.
Threats
- The biotechnology sector faces intense competition from established genome editing companies.
- Regulatory challenges may affect the development of genome editing-based therapies.
- The company's reliance on a single platform could pose risks if technology advances rapidly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.